CHIMERIC THERAPEUTICS LIMITED — Director's Dealing 2025

Aug 20, 2025

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

ntroduced 30/9/2001. Ame	nded 01/01/11
	Chimeric Therapeutics Limited (ASX: CHM)
Name of Entity:
	68 638 835 828
ABN:

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Miles Prince
Date of Last Notice:	2 July 2025

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

irector” should be disclosed in this part.
Direct or Indirect Interest		Indirect
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.		Director related entity
Date of change		19 August	2025
No. of securities held prior to change			Shares Options - - - - - -
			Shares	Options
		Direct	-	-
		Indirect	-	-
		**Total **	-	-
Class		Ordinary Shares
Number acquired			Shares Options - - 4,273,142 - 4,273,142 -
			Shares	Options
		Direct	-	-
		Indirect	4,273,142	-
		**Total **	4,273,142	-
Number disposed			Shares Options - - - - - -
			Shares	Options
		Direct	-	-
		Indirect	-	-
		Total	-	-

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation		A$0.0035 per ordinary share	A$0.0035 per ordinary share	A$0.0035 per ordinary share
No. of securities held after change			Shares Options - - 4,273,142 - 4,273,142 -
			Shares	Options
		Direct	-	-
		Indirect	4,273,142	-
		**Total **	4,273,142	-
Nature of change Example: on-market trade, off-market trade, exercise of options, issue of securities under dividend reinvestment plan, participation in buy-back		On-market trade

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Part 3 – Closed period

Were the interests in the securities or No contracts detailed above traded during a +closed period where prior written clearance was required? If so, was prior written clearance N/A provided to allow the trade to proceed during this period? If prior written clearance was N/A provided, on what date was this provided?

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011